论文部分内容阅读
目的探讨胸苷激酶1(sTK1)在肿瘤诊断和预后判断中的价值。方法利用免疫印迹增强化学发光法检测肿瘤患者组、良性疾病组和正常对照组的血清sTK1浓度及阳性率。结果sTK1诊断肿瘤的灵敏度是74·1%,特异度是97·3%;肿瘤患者组sTK1浓度为0·99~40·63pmol/L,平均浓度为4·70pmol/L,阳性率74·1%,明显高于良性疾病组(浓度为0·54~7·14pmol/L,平均浓度为1·70pmol/L,阳性率18·1%)和健康人对照组(浓度为0·14~2·15pmol/L,平均浓度为0·53pmol/L,阳性率2·73%),差异有显著性(P<0·001);肿瘤患者未经治疗组、治疗效果不佳组与治疗缓解组sTK1平均浓度比较,差异有显著性(P<0·001)。结论血清胸苷激酶1是肿瘤诊断和预后判断的有价值的指标。
Objective To investigate the value of thymidine kinase 1 (sTK1) in tumor diagnosis and prognosis. Methods The levels of sTK1 and the positive rate of serum sTK1 in tumor patients, benign disease patients and normal controls were detected by Western blotting and chemiluminescence. Results The sensitivity of sTK1 was 74.1% and the specificity was 97.3%. The sTK1 concentration of tumor patients was 0.99-40.40 pmol / L, the average concentration was 4.70 pmol / L, the positive rate was 74.1 %, Which was significantly higher than that in benign disease group (the concentration was 0.54-7.14 pmol / L, the average concentration was 1.7 pmol / L, the positive rate was 18.1%) and the healthy control group (the concentration was 0.14-2 · 15pmol / L, the average concentration was 0.53pmol / L, the positive rate of 2.73%), the difference was significant (P <0.001); tumor patients untreated group, poor treatment group and treatment response group Compared with the mean concentration of sTK1, the difference was significant (P <0.001). Conclusions Serum thymidine kinase 1 is a valuable indicator of tumor diagnosis and prognosis.